tradingkey.logo
tradingkey.logo
Buscar

Harvard Bioscience Inc

HBIO
Añadir a la lista de seguimiento
6.050USD
-0.100-1.63%
Cierre 07/01, 16:00ETCotizaciones retrasadas 15 min
27.29MCap. mercado
PérdidaP/E TTM

Más Datos de Harvard Bioscience Inc Compañía

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Información de Harvard Bioscience Inc

Símbolo de cotizaciónHBIO
Nombre de la empresaHarvard Bioscience Inc
Fecha de salida a bolsaOct 21, 2013
Director ejecutivoDuke (John D)
Número de empleados330
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 21
Dirección84 October Hill Rd
CiudadHOLLISTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01746-1371
Teléfono15088938999
Sitio Webhttps://www.harvardbioscience.com/
Símbolo de cotizaciónHBIO
Fecha de salida a bolsaOct 21, 2013
Director ejecutivoDuke (John D)

Ejecutivos de Harvard Bioscience Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Harvard Bioscience Inc?

Los cinco principales accionistas de Harvard Bioscience Inc son: Ms. Katherine Anne Eade, J.D.

¿Cuántas instituciones poseen acciones de Harvard Bioscience Inc (HBIO)?

A fecha de 2026Q1, 201 instituciones poseen acciones de Harvard Bioscience Inc, con un valor de mercado combinado de aproximadamente 2.44M, lo que representa el 54.17% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -447956.00.

¿Cuál es la mayor fuente de ganancias de Harvard Bioscience Inc?

El 2026Q1, el segmento empresarial Instruments, equipment, software and accessories generó la ganancia más alta para Harvard Bioscience Inc, ascendiendo a 78.26M y representando el 90.42% de la ganancia total.